Onconova Therapeutics, Inc. ONTX
We take great care to ensure that the data presented and summarized in this overview for Onconova Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ONTX
View all-
Orbimed Advisors LLC San Diego, CA1.05MShares$616,7030.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA707KShares$417,0830.0% of portfolio
-
Black Rock Inc. New York, NY249KShares$146,8380.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny218KShares$128,6750.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il121KShares$71,3960.0% of portfolio
-
Ubs Group Ag98.6KShares$58,1610.0% of portfolio
-
State Street Corp Boston, MA60.1KShares$35,4530.0% of portfolio
-
Northern Trust Corp Chicago, IL30.7KShares$18,0860.0% of portfolio
-
Virtu Financial LLC New York, NY27.4KShares$16,1400.0% of portfolio
-
Jane Street Group, LLC New York, NY25.1KShares$14,7860.0% of portfolio
Latest Institutional Activity in ONTX
Top Purchases
Top Sells
About ONTX
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Insider Transactions at ONTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 18
2024
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,221
-5.35%
|
$0
$0.47 P/Share
|
|
Jun 10
2024
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+11.71%
|
-
|
|
Apr 01
2024
|
Robert Redfield Acting Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+50.0%
|
-
|
|
Apr 01
2024
|
Iain D. Dukes Executive Chairman |
BUY
Grant, award, or other acquisition
|
Indirect |
1,645,100
+50.0%
|
-
|
|
Apr 01
2024
|
Iain D. Dukes Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
134,237
+41.74%
|
-
|
|
Apr 01
2024
|
Nikolay Savchuk Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
2,530,632
+50.0%
|
-
|
|
Apr 01
2024
|
Nikolay Savchuk Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
134,237
+41.74%
|
-
|
|
Apr 01
2024
|
Werner Cautreels Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+50.0%
|
-
|
|
Apr 01
2024
|
Charles David Pauza Chief Science Officer Virology |
BUY
Grant, award, or other acquisition
|
Direct |
97,500
+50.0%
|
-
|
|
Mar 14
2024
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
8,727
-10.45%
|
$0
$0.9 P/Share
|
|
Mar 14
2024
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,591
-6.72%
|
$0
$0.9 P/Share
|
|
Mar 13
2024
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Exercise of conversion of derivative security
|
Direct |
23,111
+21.67%
|
-
|
|
Mar 13
2024
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,666
+18.35%
|
-
|
|
Feb 07
2024
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
9,212
-13.23%
|
$0
$0.67 P/Share
|
|
Feb 07
2024
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
BUY
Exercise of conversion of derivative security
|
Direct |
21,320
+23.44%
|
-
|
|
Feb 07
2024
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,443
-7.55%
|
$0
$0.67 P/Share
|
|
Feb 07
2024
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
6,900
+17.58%
|
-
|
|
Aug 03
2023
|
Mark Patrick Guerin CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,422
-5.29%
|
$1,422
$1.02 P/Share
|
|
Aug 03
2023
|
Steven M Fruchtman PRESIDENT, CHIEF EXECUTIVE OFF |
SELL
Payment of exercise price or tax liability
|
Direct |
4,744
-8.94%
|
$4,744
$1.01 P/Share
|
|
Aug 02
2023
|
Mark Patrick Guerin CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
4,750
+15.02%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 65.5K shares |
|---|---|
| Grant, award, or other acquisition | 4.84M shares |
| Payment of exercise price or tax liability | 25.2K shares |
|---|